|
|
Volumn 348, Issue 6, 2003, Pages
|
|
Aspirin, clopidogrel, or both for secondary prevention of coronary disease.
a
a
NONE
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ACETYLSALICYLIC ACID;
ANTITHROMBOCYTIC AGENT;
CLOPIDOGREL;
DRUG DERIVATIVE;
TICLOPIDINE;
CORONARY ARTERY DISEASE;
COST BENEFIT ANALYSIS;
DRUG COMBINATION;
ECONOMICS;
HUMAN;
NOTE;
RISK;
STATISTICAL ANALYSIS;
DRUG COST;
HEART INFARCTION;
DRUG INDUSTRY;
FEE;
HEALTH CARE COST;
QUALITY ADJUSTED LIFE YEAR;
ASPIRIN;
CORONARY DISEASE;
COST-BENEFIT ANALYSIS;
DATA INTERPRETATION, STATISTICAL;
DRUG THERAPY, COMBINATION;
HUMANS;
PLATELET AGGREGATION INHIBITORS;
RISK;
TICLOPIDINE;
DRUG COSTS;
MYOCARDIAL INFARCTION;
DRUG INDUSTRY;
FEES, PHARMACEUTICAL;
HEALTH EXPENDITURES;
QUALITY-ADJUSTED LIFE YEARS;
|
|
EID: 0037421692
PISSN: None
EISSN: 15334406
Source Type: Journal
DOI: 10.1056/NEJM200302063480616 Document Type: Note |
|
Times cited : (7)
|
|
References (0)
|
